CellVoyant Technologies
CellVoyant Technologies is an AI-native biotech company building a Cell Predictive AI Platform (FateView™ and FateDrive™) that applies computer vision and machine learning to label-free live-cell imaging for cell therapy developers and biopharmaceutical manufacturers.
- Company typePrivate
- Founded2021
- HeadquartersBristol, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What CellVoyant Technologies does
CellVoyant Technologies Limited is a Bristol, UK-based AI biotechnology company spun out of the University of Bristol that develops a Cell Predictive AI Platform for cell-based therapeutic developers and biopharmaceutical manufacturers. The company's core product proposition is replacing slow, endpoint-assay-driven cell culture workflows with predictive, label-free live-cell imaging analytics, targeting pain points around late failure detection, high batch variability, and costly trial-and-error iteration in stem cell and cell therapy development pipelines.
The platform is delivered through two integrated products. FateView™ is a cloud-based, secure SaaS platform where users upload label-free microscopy images (brightfield or phase-contrast) and receive AI-generated predictions of current and future cell states, critical quality attributes, and likely experimental outcomes; features include cell detection, colony detection, pluripotency assessment, and differentiation tracking, accessed via browser or API. FateDrive™ is an AI-driven process optimization service that models, simulates, and prioritizes process conditions in silico, and integrates with FateView™ for closed-loop optimization when connected to automation systems such as Automata's LINQ™ platform. The underlying technology combines proprietary computer vision and machine learning models trained on large-scale time-series imaging datasets, with reported performance gains of up to 8× higher yield, 60% fewer failed experiments, and 40% less waste in partner workflows.
CellVoyant operates a hybrid go-to-market combining product-led growth (30-day free trial of FateView™ with no credit card required, followed by quote-based subscription) and enterprise field sales targeting biotech and pharmaceutical companies developing cell-based therapies. Revenue streams comprise SaaS subscriptions on FateView™, subscription-based FateDrive™ optimization engagements, and professional services for custom assay development. The company is venture-backed (a £7.6M seed round led by Octopus Ventures in January 2024, with Air Street Capital, Horizons Ventures, Compound, and Verve Ventures participating), has a team of ~14 scientists and engineers, and is pursuing strategic partnerships across the iPSC supply chain (Pluristyx, Axol Bioscience) and laboratory automation (Automata) to embed its platform in customer bioprocess workflows.
CellVoyant Technologies firmographics
Firmographics- Name
- CellVoyant Technologies
- Legal name
- CellVoyant Technologies Limited
- Website
- https://cellvoyant.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CellVoyant Technologies is an AI-native biotech company building a Cell Predictive AI Platform (FateView™ and FateDrive™) that applies computer vision and machine learning to label-free live-cell imaging for cell therapy developers and biopharmaceutical manufacturers.
- Ownership category
- akta.pro rank
CellVoyant Technologies industry classification
Industry- Product category
- AI Cell Analytics Software
- NAICS
- Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Scenario Planning, Forecasting Platforms & Planning Intelligence (HDAAAHAL)
- akta.pro secondary industries
- Model Hosting, Serving & Inference Platforms (HDAAACAB), Model Deployment, Serving & Inference Platforms (HDAAABAF), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
Keywords
Where CellVoyant Technologies is headquartered
LocationHeadquarters
- HQ city
- Bristol
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
CellVoyant Technologies business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- FateView™ SaaS Platform: Cloud-based subscription platform offering predictive cell analytics. Users access via secure browser interface or API with tiered pricing based on usage. Free trial available for initial onboarding, followed by paid subscription.
- FateDrive™ Optimization Services: AI-driven process optimization service working alongside customer teams on science-led optimization. Combines predictive inputs from FateView with in-silico modeling to guide experimental and manufacturing decisions.
- Custom Assay Development: Tailored assay development for specific phenotypes of interest and custom readouts. Professional service engagement for organizations with specialized process requirements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free Trial - 30-day access to core features |
| Subscription | Annual | Paid Subscription - Full platform access |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
CellVoyant Technologies product offering
Product offeringCore offering
CellVoyant sells an AI Cell Predictive Platform comprising two products: FateView™, a cloud-based SaaS that applies computer vision and machine learning to label-free live-cell microscopy images to predict cell state, critical quality attributes (CQAs), and likely outcomes; and FateDrive™, an AI-driven process optimization service that models and simulates cell culture conditions to guide experimental and manufacturing decisions and integrates with FateView for closed-loop workflows.
Product overview
CellVoyant operates as an AI-First company offering a Cell Predictive AI Platform consisting of two integrated core products: FateView™ and FateDrive™. FateView™ is a cloud-based platform providing label-free AI image analysis to predict cell state and outcomes from live-cell microscopy images. FateDrive™ is an AI-driven optimisation service that models and simulates process conditions to guide decisions. Together, they enable adaptive process control by combining real-time measurement with model-driven optimisation, supporting closed-loop workflows when integrated with automation systems like Automata LINQ™.
Differentiator
Problem solved
Functional benefit
Brands
- FateView™: AI-powered predictive cell analytics platform for label-free live-cell image analysis to infer cell state and likely outcomes
- FateDrive™
Products and services
- FateView™ Cloud-based, label-free AI image analysis SaaS platform that ingests live-cell transmitted-light microscopy images and returns predictions of current and future cell states, critical quality attributes (CQAs), and likely experimental outcomes. Targeted at biotech and pharmaceutical R&D teams developing cell-based therapeutics, including stem cell, iPSC-derived, and CAR-T programs.
- FateDrive™ AI-driven process optimization service that models, simulates, and prioritizes cell culture process conditions to guide experimental and manufacturing decisions. Works alongside customer teams to deliver science-led optimization and integrates with FateView for real-time, closed-loop bioprocess optimization. Targeted at bioprocess development and manufacturing teams in cell therapy and biologics organizations.
- Custom Assay Development
Quantifiable outcome
- Up to 60% fewer failed experiments by identifying differentiation failure before typical assays detect issues
- +4 more outcomes
Companies that use CellVoyant Technologies
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
CellVoyant Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature5 records
CellVoyant Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Axol BiosciencecoreStrategic collaboration to develop AI-guided predictive imaging assays for cardiomyocyte manufacturing. Integration of FateView platform with Axol Bioscience's iPSC differentiation and heart chamber-specific cardiomyocyte production expertise. Focus on non-invasive, label-free methods for predicting and guiding differentiation processes to generate highly pure cell populations at scale.
- PluristyxcoreStrategic partnership combining CellVoyant's predictive AI platform with Pluristyx's human iPSC technologies to co-develop AI-characterised iPSC products. Joint initiative to integrate continuous, non-destructive insights onto traditional manufacturing workflows, moving toward more data-rich, predictive assessments of cell behavior for enhanced cell therapy development.
- AutomatacoreStrategic partnership integrating FateDrive with Automata's LINQ lab automation platform to enable AI-powered, closed-loop cell culture optimisation. The collaboration brings together predictive analytics, in-silico optimisation, and modular lab automation for autonomous cell culture workflows. Demonstrated 8× improvement in differentiation efficiency in cardiomyocyte differentiation.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
CellVoyant Technologies competitors and assessment
Company assessmentEmerging players
- Culture Biosciences: Biotech offering automated bioreactor and bioprocess development services with cloud-based monitoring. Comparable in bringing digital and AI-driven optimization to bioprocess workflows.
- AbCellera Biologics: AI-driven antibody and biologics discovery platform using high-throughput experimentation and ML. Adjacent AI-for-biotech-discovery competitor with overlapping biopharma customer base.
Broad incumbents
- Tempus AI: AI and data platform for life sciences and pharma with broad applications across R&D and clinical workflows. Larger, broader incumbent applying AI to pharma and biotech data at scale.
- Cytiva (Danaher): Major supplier of cell therapy manufacturing and bioprocess solutions to pharma and biotech. Incumbent in the cell therapy manufacturing stack that CellVoyant's FateDrive optimization platform targets.
- Owkin: AI platform for biopharma R&D combining multimodal data and ML to accelerate drug development. Comparable AI-for-biopharma enterprise go-to-market with pharma customers.
- Sartorius: Large bioprocess solutions provider including cell line development, analytical instruments, and bioprocess automation. Established incumbent with overlapping customers in cell therapy and bioprocess analytics.
Direct peers
- CytoReason: AI company building cell-biology models for biopharma R&D and drug development. Direct comparable in applying AI to predict cellular behavior and disease mechanisms for pharma customers.
- Recursion Pharmaceuticals: AI-driven drug discovery company leveraging high-content imaging and foundation models across large-scale cellular datasets. Comparable in pairing AI with image-based cellular phenotyping for therapeutic discovery.
- Insitro: AI-native biotech using machine learning and high-content cellular imaging to model disease and discover therapeutics. Closest comparable in combining AI/computer vision with cell biology at scale for biopharma R&D.
- PhenomeX (formerly Berkeley Lights): Provider of single-cell analysis and functional cell biology instrumentation used in cell therapy development and bioprocess optimization. Comparable in serving cell therapy developers with imaging-based analytics tools.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
CellVoyant Technologies social profiles
Digital presenceCellVoyant Technologies compliance and trust
Trust signalCompliance2 records
CellVoyant Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
CellVoyant Technologies leadership team
Management profileNumber of profiles
Profiles10 records
CellVoyant Technologies funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CellVoyant Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CellVoyant Technologies
What does CellVoyant Technologies do?
CellVoyant sells an AI Cell Predictive Platform comprising two products: FateView™, a cloud-based SaaS that applies computer vision and machine learning to label-free live-cell microscopy images to predict cell state, critical quality attributes (CQAs), and likely outcomes; and FateDrive™, an AI-driven process optimization service that models and simulates cell culture conditions to guide experimental and manufacturing decisions and integrates with FateView for closed-loop workflows.
Is CellVoyant Technologies a public or private company?
CellVoyant Technologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was CellVoyant Technologies founded?
CellVoyant Technologies was founded in 2021. It employs 11 to 50 people.
Where is CellVoyant Technologies based?
CellVoyant Technologies is headquartered in Bristol, United Kingdom, in the Europe region.
How does CellVoyant Technologies make money?
Three revenue lines are on record. FateView™ SaaS Platform is the primary driver. The others are fateDrive™ Optimization Services and custom Assay Development.
Who are CellVoyant Technologies's main competitors?
Emerging players on record are Culture Biosciences and AbCellera Biologics. Broad incumbents are Tempus AI, Cytiva (Danaher), Owkin and Sartorius. Direct peers are CytoReason, Recursion Pharmaceuticals, Insitro and PhenomeX (formerly Berkeley Lights).
Does CellVoyant Technologies have an API?
Yes. FateView™ provides flexible platform access via secure browser interface or API, designed to integrate seamlessly with existing workflows. Predictive analytics and metadata can be exported for use in automation systems, data platforms, or adaptive culture management pipelines. Developer documentation is at fateview.cellvoyant.com.
What industry is CellVoyant Technologies in?
CellVoyant Technologies's product category is AI Cell Analytics Software. Its primary akta.pro industry code is HDAAAHAL, Scenario Planning, Forecasting Platforms & Planning Intelligence, with a secondary code of HDAAACAB, Model Hosting, Serving & Inference Platforms. Its NAICS code is 54151 and its SIC code is 8731.